Detalhe da pesquisa
1.
An efficient algorithm to determine the optimal two-stage randomized multinomial designs in oncology clinical trials.
J Biopharm Stat
; 21(1): 56-65, 2011 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-21191854
2.
Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.
N Engl J Med
; 354(24): 2542-51, 2006 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-16775235
3.
Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies.
J Clin Oncol
; 21(21): 3955-64, 2003 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-14517187
4.
Survival prediction in everolimus-treated patients with metastatic renal cell carcinoma incorporating tumor burden response in the RECORD-1 trial.
Eur Urol
; 64(6): 994-1002, 2013 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-23219086
5.
Letter to the Editor re Yu and Holmgren. Traditional endpoint of progression-free survival (PFS) may not be appropriate for evaluating cytostatic agents combined with chemotherapy in cancer clinical trials.
Contemp Clin Trials
; 28(5): 674, 2007 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-17449334
6.
Pharmacokinetic drug interaction between AEE788 and RAD001 causing thrombocytopenia in patients with glioblastoma.
Cancer Chemother Pharmacol
; 69(1): 281-7, 2012 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-21984222
7.
Phase I study of AEE788, a novel multitarget inhibitor of ErbB- and VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patients.
Cancer Chemother Pharmacol
; 69(6): 1507-18, 2012 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-22392572
8.
Using pharmacokinetic and pharmacodynamic data in early decision making regarding drug development: a phase I clinical trial evaluating tyrosine kinase inhibitor, AEE788.
Clin Cancer Res
; 18(22): 6364-72, 2012 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-23014528
9.
Statistical methods for a phase II oncology trial with a growth modulation index (GMI) endpoint.
Contemp Clin Trials
; 32(1): 99-107, 2011 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-20920605
10.
Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancer.
J Clin Oncol
; 26(16): 2674-82, 2008 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-18509179